STAT+: Colombia issues a compulsory license for an HIV medicine and ‘plants a flag for global health equity’
After months of deliberation, the Colombian government has issued a compulsory license for an HIV…
Category: Pharmalot
.jpg)
STAT+: Pharmalittle: We’re reading about GLP-1 spending, biosimilar patient costs, and more
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this…
STAT+: Biosimilars haven’t always yielded lower out-of-pocket costs for patients, study finds
Two years after biosimilars became available in the U.S., a higher proportion of patients using…
STAT+: Pharmalittle: We’re reading about Lilly buying a plant, a Pfizer antibiotic, and more
Top of the morning to you, and a fine one it is. There is nothing…
.jpg)
STAT+: Pharmalittle: We’re reading about an OptumRx contract, 340B dispute resolution, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about plans for generic Wegovy, cough syrup warnings, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: New antibiotics were underprescribed for hard-to-treat infections, study finds
Although U.S. regulators approved several new antibiotics for combating hard-to-treat bacteria during a recent five-year…
STAT+: Pharmalittle: We’re reading about BIO’s China challenge, Zepbound shortages, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: Animal rights group urges SEC to investigate Charles River over monkey purchases
A leading animal rights group has asked securities regulators to investigate Charles River Laboratories for…
STAT+: Pharmalittle: We’re reading about Lilly’s Zepbound for sleep apnea, the FDA budget, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Pharmalittle: We’re reading about CVS and Humira biosimilars, Schumer’s broken insulin promise, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: Thanks to CVS, a biosimilar version of AbbVie’s Humira is grabbing huge market share
The number of new prescriptions written for biosimilar versions of the Humira rheumatoid arthritis treatment,…
STAT+: Pharmalittle: We’re reading about a J&J cough syrup, a Pfizer and Moderna patent suit, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Colorado lawmakers revise effort to exempt rare disease drugs from state cost caps
In response to controversy, a group of Colorado lawmakers is abandoning a bill that would…
STAT+: Pharmalittle: We’re reading about AstraZeneca CEO pay, alternatives to WuXi and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about drug shortages, Medicare spending on an Alzheimer’s drug, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, despite…
STAT+: European Parliament votes in favor of updated pharma legislation, prompting mixed reactions
The European Parliament has voted overwhelmingly to adopt legislation that is supposed to transform the…
STAT+: Drug shortages reached a record high as 2023 drew to a close
The number of ongoing and active drug shortages in the U.S. stood at 323 during…
STAT+: Regeneron accused by Justice Department of manipulating Medicare pricing
The U.S. Department of Justice filed a lawsuit accusing Regeneron Pharmaceuticals of manipulating Medicare pricing…
STAT+: Pharmalittle: We’re reading about a 486% drug price hike, AstraZeneca CEO pay, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Did you say 486%? Why one company thinks such a price hike for its drug is justified
In an era when huge price hikes for prescription drugs are almost guaranteed to draw…
STAT+: Virginia governor vetoes plans to create a prescription drug affordability board
Virginia Gov. Glenn Youngkin vetoed a bill that would have created a new entity for…
STAT+: Biden administration urged to license prostate cancer drug patents in a bid to lower its cost
In the latest gambit to lower the cost of a pricey medicine, three advocacy groups…
STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: FDA agrees to review a rare disease drug that its developer was about to give up on
File this under “Not a moment too soon.” After years of back-and-forth deliberations, the U.S….
STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about Amylyx pulling its ALS drug, GLP-1 drugs for Parkinson’s, and more
Top of the morning to you, and a fine one it is. After two days…
STAT+: Pharmalittle: We’re reading about a White House drug-shortage plan, a Genmab deal, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Pharmalittle: We’re reading about a European probe into vaccine talks; net drug prices falling, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Net prices for medicines fell considerably in 2023’s last quarter, mostly thanks to Humira biosimilars
The net prices that health plans paid for medicines — after subtracting rebates, discounts, and…
STAT+: Pharmalittle: We’re reading about AstraZeneca’s CEO pay, an ALS drug spat in the U.K., and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about Wegovy insurance coverage, Zepbound shortages, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Payments by drug and device makers to doctors remain widespread, but also vary considerably
The financial ties between drug and device makers and some physicians remains pervasive, despite concerns…
STAT+: Pharmalittle: We’re reading about a GLP-1 side effect, U.K. clinical trial transparency, and more
Top of the morning to you and a fine one it is. Despite cloudy skies…
STAT+: U.K. becomes the first country to release detailed data on sponsors that fail to register clinical trials
The United Kingdom has released comprehensive data showing which institutions have failed to register their…
STAT+: Pharmalittle: We’re reading about abortion pill arguments, a Merck drug approval, and more
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this…
STAT+: AstraZeneca sues Arkansas over the role of pharmacies in a federal discount drug program
AstraZeneca filed a lawsuit seeking to block an Arkansas law that requires the company to…
STAT+: FDA is still struggling to inspect clinical research sites, watchdog finds
The U.S. Food and Drug Administration’s oversight of clinical research in hospitals and clinics has…
STAT+: European antitrust regulators probe Zoetis over pain drug for dogs
The European Commission has opened a formal antitrust investigation to determine whether Zoetis, one of…
STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more
Rise and shine, everyone, another busy day is on the way. How so? The evidence…
STAT+: Amgen sues Colorado over its prescription drug affordability board
Amgen has filed a lawsuit accusing a Colorado state board of violating the U.S. Constitution…
STAT+: Chick-fil-A drops a ‘No Antibiotic Ever’ pledge on chicken over supply issues
Chick-fil-A, one of the largest fast-food restaurants in the U.S., is easing its commitment to…
STAT+: Pharmalittle: We’re reading about a Novo Nordisk deal, a Regeneron setback, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, FDA syringe warnings, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, GSK asthma inhalers, and more
Top of the morning to you, and a fine one it is. Although quite chilly…
STAT+: Pharma companies and their allies seek to exempt orphan drugs from state pricing limits
As more states create dedicated boards to cap the costs of medicines, some drugmakers and…
STAT+: Pharmalittle: We’re reading about Europe’s pharma reform, weight-loss meds, and more
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: J&J sues former employee for allegedly taking thousands of documents to a new job at Pfizer
Johnson & Johnson has accused a long-standing employee of taking thousands of confidential files about…
STAT+: Pharmalittle: We’re reading about an AstraZeneca deal, a WHO pandemic pact, and more
Rise and shine, everyone, another busy day is on the way. Already, the official mascots…